A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása

Béla Kajtár, G. Méhes, Pál Jáksó, L. Kereskai, János Lśzló Iványi, Hajna Losonczy, Miklós Egyed, Péter Tóth, Antal Tóth, Zoltán Gasztonyi, Mária Dömötör, Lśzló Pajor

Research output: Article

2 Citations (Scopus)

Abstract

The t(9;22) translocation, which results in a fusion protein with abnormal tyrosine-kinase activity, plays a central role in the pathogenesis of chronic myeloid leukemia. The selective inhibition of this chimeric protein with imatinib-mesylate is an efficient therapeutic option, haematologic and cytogenetic responses can be achieved in most of the patients. The primary goal of monitoring the disease is to assess the efficiency of the therapy, to highlight those patients, whose survival may be improved by modifying treatment. Three methods are widely used for the genetic monitoring of chronic myeloid leukemia. With karyotyping, the proliferating bone marrow cells can be evaluated. The use of fluorescent in situ hybridization makes the cytogenetic analysis of each cell within the sample possible. Real-time quantitative polymerase chain reaction is capable of quantifying residual leukemia far below the sensitivity of cytogenetics. The results of these three methods have different biological meanings, thus, for the interpretation of the results, the knowledge of the characteristics, the benefits and the drawbacks of the methods is required. The present study shows the most important characteristics of these methods based on the literature and data acquired from 1165 samples of 197 patients detected by the authors.

Original languageHungarian
Pages (from-to)963-970
Number of pages8
JournalOrvosi Hetilap
Volume147
Issue number21
Publication statusPublished - máj. 28 2006

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Karyotyping
Cytogenetic Analysis
Fluorescence In Situ Hybridization
Bone Marrow Cells
Protein-Tyrosine Kinases
Real-Time Polymerase Chain Reaction
Leukemia
Proteins
Therapeutics
Survival

Keywords

  • Chronic myeloid leukemia
  • FISH
  • Karyotyping
  • Real-time PCR

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kajtár, B., Méhes, G., Jáksó, P., Kereskai, L., Iványi, J. L., Losonczy, H., ... Pajor, L. (2006). A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása. Orvosi Hetilap, 147(21), 963-970.

A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása. / Kajtár, Béla; Méhes, G.; Jáksó, Pál; Kereskai, L.; Iványi, János Lśzló; Losonczy, Hajna; Egyed, Miklós; Tóth, Péter; Tóth, Antal; Gasztonyi, Zoltán; Dömötör, Mária; Pajor, Lśzló.

In: Orvosi Hetilap, Vol. 147, No. 21, 28.05.2006, p. 963-970.

Research output: Article

Kajtár, B, Méhes, G, Jáksó, P, Kereskai, L, Iványi, JL, Losonczy, H, Egyed, M, Tóth, P, Tóth, A, Gasztonyi, Z, Dömötör, M & Pajor, L 2006, 'A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása', Orvosi Hetilap, vol. 147, no. 21, pp. 963-970.
Kajtár B, Méhes G, Jáksó P, Kereskai L, Iványi JL, Losonczy H et al. A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása. Orvosi Hetilap. 2006 máj. 28;147(21):963-970.
Kajtár, Béla ; Méhes, G. ; Jáksó, Pál ; Kereskai, L. ; Iványi, János Lśzló ; Losonczy, Hajna ; Egyed, Miklós ; Tóth, Péter ; Tóth, Antal ; Gasztonyi, Zoltán ; Dömötör, Mária ; Pajor, Lśzló. / A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 21. pp. 963-970.
@article{381178842f074ca9980aaf2c09e7bfdf,
title = "A kr{\'o}nikus myeloid leukaemia citogenetikai {\'e}s molekul{\'a}ris monitoroz{\'a}sa",
abstract = "The t(9;22) translocation, which results in a fusion protein with abnormal tyrosine-kinase activity, plays a central role in the pathogenesis of chronic myeloid leukemia. The selective inhibition of this chimeric protein with imatinib-mesylate is an efficient therapeutic option, haematologic and cytogenetic responses can be achieved in most of the patients. The primary goal of monitoring the disease is to assess the efficiency of the therapy, to highlight those patients, whose survival may be improved by modifying treatment. Three methods are widely used for the genetic monitoring of chronic myeloid leukemia. With karyotyping, the proliferating bone marrow cells can be evaluated. The use of fluorescent in situ hybridization makes the cytogenetic analysis of each cell within the sample possible. Real-time quantitative polymerase chain reaction is capable of quantifying residual leukemia far below the sensitivity of cytogenetics. The results of these three methods have different biological meanings, thus, for the interpretation of the results, the knowledge of the characteristics, the benefits and the drawbacks of the methods is required. The present study shows the most important characteristics of these methods based on the literature and data acquired from 1165 samples of 197 patients detected by the authors.",
keywords = "Chronic myeloid leukemia, FISH, Karyotyping, Real-time PCR",
author = "B{\'e}la Kajt{\'a}r and G. M{\'e}hes and P{\'a}l J{\'a}ks{\'o} and L. Kereskai and Iv{\'a}nyi, {J{\'a}nos Lśzl{\'o}} and Hajna Losonczy and Mikl{\'o}s Egyed and P{\'e}ter T{\'o}th and Antal T{\'o}th and Zolt{\'a}n Gasztonyi and M{\'a}ria D{\"o}m{\"o}t{\"o}r and Lśzl{\'o} Pajor",
year = "2006",
month = "5",
day = "28",
language = "Hungarian",
volume = "147",
pages = "963--970",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "21",

}

TY - JOUR

T1 - A krónikus myeloid leukaemia citogenetikai és molekuláris monitorozása

AU - Kajtár, Béla

AU - Méhes, G.

AU - Jáksó, Pál

AU - Kereskai, L.

AU - Iványi, János Lśzló

AU - Losonczy, Hajna

AU - Egyed, Miklós

AU - Tóth, Péter

AU - Tóth, Antal

AU - Gasztonyi, Zoltán

AU - Dömötör, Mária

AU - Pajor, Lśzló

PY - 2006/5/28

Y1 - 2006/5/28

N2 - The t(9;22) translocation, which results in a fusion protein with abnormal tyrosine-kinase activity, plays a central role in the pathogenesis of chronic myeloid leukemia. The selective inhibition of this chimeric protein with imatinib-mesylate is an efficient therapeutic option, haematologic and cytogenetic responses can be achieved in most of the patients. The primary goal of monitoring the disease is to assess the efficiency of the therapy, to highlight those patients, whose survival may be improved by modifying treatment. Three methods are widely used for the genetic monitoring of chronic myeloid leukemia. With karyotyping, the proliferating bone marrow cells can be evaluated. The use of fluorescent in situ hybridization makes the cytogenetic analysis of each cell within the sample possible. Real-time quantitative polymerase chain reaction is capable of quantifying residual leukemia far below the sensitivity of cytogenetics. The results of these three methods have different biological meanings, thus, for the interpretation of the results, the knowledge of the characteristics, the benefits and the drawbacks of the methods is required. The present study shows the most important characteristics of these methods based on the literature and data acquired from 1165 samples of 197 patients detected by the authors.

AB - The t(9;22) translocation, which results in a fusion protein with abnormal tyrosine-kinase activity, plays a central role in the pathogenesis of chronic myeloid leukemia. The selective inhibition of this chimeric protein with imatinib-mesylate is an efficient therapeutic option, haematologic and cytogenetic responses can be achieved in most of the patients. The primary goal of monitoring the disease is to assess the efficiency of the therapy, to highlight those patients, whose survival may be improved by modifying treatment. Three methods are widely used for the genetic monitoring of chronic myeloid leukemia. With karyotyping, the proliferating bone marrow cells can be evaluated. The use of fluorescent in situ hybridization makes the cytogenetic analysis of each cell within the sample possible. Real-time quantitative polymerase chain reaction is capable of quantifying residual leukemia far below the sensitivity of cytogenetics. The results of these three methods have different biological meanings, thus, for the interpretation of the results, the knowledge of the characteristics, the benefits and the drawbacks of the methods is required. The present study shows the most important characteristics of these methods based on the literature and data acquired from 1165 samples of 197 patients detected by the authors.

KW - Chronic myeloid leukemia

KW - FISH

KW - Karyotyping

KW - Real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=33747612616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747612616&partnerID=8YFLogxK

M3 - Article

C2 - 16812971

AN - SCOPUS:33747612616

VL - 147

SP - 963

EP - 970

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 21

ER -